Eisai finds an exit from Aduhelm, with small royalties if it ever nabs coverage - Endpoints News

With less than a month to go to the final national coverage determination from CMS, Biogen's Japanese partner Eisai is essentially cutting its losses on their FDA-approved Alzheimer's drug. The two companies on Wednesday unveiled a reworked partnership for th…

In a September interview with Endpoints News, Cytiva CMO Conor McKechnie said that the company was focusing on in-region, for-region manufacturing as the biopharma world felt the impact of supply woe… [+585 chars]

full article...